TGFB1 and systemic sclerosis: Given the capability of TGF-β to promote the activation of PI3K/mTOR pathway [117], it has been demonstrated that the inhibition of mTOR complex activity by rapamycin was able to prevent EndoMT in vitro and ex vivo [135,136] and to improve fibrosis in two different mouse models of SSc [137].